BlueWillow Biologics

Executive Summary

BlueWillow Biologics is a clinical-stage biotechnology company pioneering intranasal vaccine and adjuvant technologies through its proprietary NanoVax® platform (W805EC oil-in-water adjuvant). Founded in 2007 and headquartered in Ann Arbor, Michigan, the company aims to transform infectious disease prevention and treatment by enabling needle-free, mucosal immunization that induces both systemic and local immune responses. Its lead program is in Phase 1 clinical development, positioning BlueWillow as one of the most advanced intranasal adjuvant platforms in the pipeline. The technology holds promise for pandemic preparedness and for improving vaccine efficacy against respiratory pathogens, potentially offering advantages in ease of administration, storage, and patient compliance.

Upcoming Catalysts (preview)

• Q3 2026Completion and data readout from Phase 1 trial of lead intranasal vaccine candidate60% success
• TBDStrategic partnership or licensing deal for NanoVax® platform with a major pharmaceutical company30% success
• Q4 2026Award of non-dilutive funding (e.g., BARDA or NIH grant) for pandemic preparedness development50% success